There are 205 resources available
Q&A and discussion
Session: Oral abstract session 2
Resources:
Webcast
How do we pick a recommended dose: Safe may be, but optimised?
Presenter: Elena Garralda
Session: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development
Resources:
Slides
Webcast
Early evaluation of efficacy in phase I trials: Persevere or halt the programme?
Presenter: Jordi Rodon
Session: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development
Resources:
Slides
Webcast
Q&A and discussion
Session: Workshop in collaboration with ESMO YOC: Evaluation of phase I data at the end of the study for next planning of drug development
Resources:
Webcast
The clinical/academia perspective
Presenter: Stefan Michiels
Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views
Resources:
Slides
Webcast
Molecular imaging to select patients for treatment with radiopharmaceuticals
Presenter: Michael Hofman
Session: Radiotheranostics
Resources:
Slides
Webcast
The regulator perspective
Presenter: Harpreet Singh
Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views
Resources:
Slides
Webcast
Navigating logistical challenges in radiopharmaceutical supply for treatments: Ensuring sufficient supply, durability and timely delivery from manufacture to infusion
Presenter: Wim Oyen
Session: Radiotheranostics
Resources:
Slides
Webcast
The biotech perspective
Presenter: Robert Doebele
Session: Fast tracking drug development by early screening for tumour-agnostic potential: Trialist, sponsor and regulator views
Resources:
Slides
Webcast
Treatment with radiopharmaceutical targeting neuroendocrine cancers
Presenter: Enrique Grande
Session: Radiotheranostics
Resources:
Slides
Webcast